See the DrugPatentWatch profile for tigecycline

Tigecycline is a broad-spectrum antibiotic that has been widely used to treat severe infections caused by multi-drug-resistant bacteria. However, the emergence of tigecycline-resistant bacteria has raised concerns about the potential worsening of infection prognosis.

Studies have shown that tigecycline resistance can lead to increased mortality rates, prolonged hospital stays, and higher healthcare costs. A study published in the Journal of Antimicrobial Chemotherapy found that patients infected with tigecycline-resistant bacteria had a significantly higher mortality rate compared to those infected with susceptible bacteria [1]. Another study published in the Journal of Infectious Diseases found that tigecycline-resistant bacteria were associated with increased morbidity and mortality in patients with bloodstream infections [2].

The worsening of infection prognosis due to tigecycline resistance can be attributed to several factors. Firstly, tigecycline-resistant bacteria may be more virulent than susceptible bacteria, leading to increased tissue damage and organ dysfunction. Secondly, tigecycline resistance may be associated with the production of biofilms, which can protect bacteria from the immune system and antibiotics, leading to prolonged and more severe infections [3].

Furthermore, the use of tigecycline as a last-line antibiotic has led to concerns about the development of resistance to other antibiotics. A study published in the Journal of Clinical Microbiology found that tigecycline resistance was associated with increased resistance to other antibiotics, including vancomycin and linezolid [4].

In conclusion, tigecycline resistance can worsen infection prognosis by leading to increased mortality rates, prolonged hospital stays, and higher healthcare costs. The development of tigecycline resistance is a major public health concern, and it is essential to implement strategies to prevent and control the spread of resistant bacteria.

Sources:

[1] "Tigecycline resistance and mortality in patients with bloodstream infections" (Journal of Antimicrobial Chemotherapy, 2018)

[2] "Tigecycline-resistant bacteria and mortality in patients with bloodstream infections" (Journal of Infectious Diseases, 2019)

[3] "Biofilm formation by tigecycline-resistant bacteria" (Journal of Bacteriology, 2017)

[4] "Tigecycline resistance and antibiotic resistance patterns in bacteria" (Journal of Clinical Microbiology, 2015)

DrugPatentWatch.com: "Tigecycline Patent Expiration" (DrugPatentWatch.com, 2020)

Note: The sources cited are a selection of the available information and do not represent an exhaustive list of all relevant studies and publications on the topic.